Please login to the form below

Not currently logged in
Email:
Password:

Ozempic

This page shows the latest Ozempic news and features for those working in and with pharma, biotech and healthcare.

Lilly’s Trulicity scores CV reduction indication in the US

Lilly’s Trulicity scores CV reduction indication in the US

The new MACE approval could help Lilly in its fight for market share with other GLP-1 agonists, including Novo Nordisk’s once-weekly drug Ozempic (semaglutide).

Latest news

  • New drugs drive Novo Nordisk despite insulin price pressures New drugs drive Novo Nordisk despite insulin price pressures

    This included a boost from GLP-1 agonist  Ozempic (semaglutide) which has been climbing solidly since its launch, as demand increases for the drug. ... We are very satisfied with the financial performance in 2019. The results reflect an accelerated

  • Novo Nordisk gets MACE prevention claim for Ozempic in US Novo Nordisk gets MACE prevention claim for Ozempic in US

    Key product for the future growth of Novo's diabetes franchise. The FDA has approved new labelling for Novo Nordisk’s diabetes drug Ozempic that indicates it can reduce the risk ... EvaluatePharma has previously predicted that Ozempic could become a

  • Novo bolstered by new diabetes, obesity products Novo bolstered by new diabetes, obesity products

    Despite facing tough competition from its class rivals, particularly first-to-market Trulicity (dulaglutide) from Eli Lilly, Ozempic has continued to be a source of growth for Novo. ... status of Ozempic following the successful launch in the USA; two

  • Novo Nordisk taps Noom for digital help with its push into obesity Novo Nordisk taps Noom for digital help with its push into obesity

    The weekly injectable has been approved for type 2 diabetes as Ozempic since 2017, and the  oral formulation just got a green light from the FDA – its first world market – also

  • Novo Nordisk gets FDA okay for new diabetes hope Novo Nordisk gets FDA okay for new diabetes hope

    injectable Ozempic – also based on semaglutide – and once-daily shot Victoza (liraglutide). ... Sales of Victoza fell 5% in the first half of the year to around $1.6bn, and while the decline was more than offset by growth by Ozempic’s $550m

More from news
Approximately 11 fully matching, plus 13 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

Could formulary intelligence be your brand differentiator?
Proprietary research, and the COVID-19 experience, shows how formulary intelligence can drive competitive advantage at launch...
Lara Meyer
How COVID-19 is accelerating the threat of antimicrobial resistance
Why antimicrobial resistance needs to be addressed with the same urgency as COVID-19...
Improve clinical trials through patient journey mapping
Could patient journey mapping be your solution to improving clinical study recruitment and retention? While awareness of clinical studies is low across the population, it’s not the only issue. It’s...

Infographics